Korro Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Korro Bio, Inc. (KRRO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-06
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $0.00.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $600.00K, a 83.33% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $100.00K, a 90.00% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $1.00M, a 80.00% decline from fiscal 2024.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $5.00M, a 1566.67% increase from fiscal 2023.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $300.00K, a 200.00% increase from fiscal 2022.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $100.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $600.00K derived: sum of 3 quarters · filed 2026-08-06 | $700.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $600.00K derived: sum of 2 quarters · filed 2026-05-07 | $700.00K derived: sum of 3 quarters · filed 2026-05-07 | $700.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $700.00K derived: sum of 2 quarters · filed 2026-03-12 | $700.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.00M 10-K · filed 2026-03-12 |
| 2025-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $100.00K derived: sum of 2 quarters · filed 2026-08-06 | $400.00K 10-Q · filed 2025-11-12 | $4.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $300.00K 10-Q · filed 2026-08-06 | $3.90M derived: sum of 3 quarters · filed 2026-08-06 | $4.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $300.00K 10-Q · filed 2026-05-07 | $3.90M derived: sum of 2 quarters · filed 2026-05-07 | $4.90M derived: sum of 3 quarters · filed 2026-05-07 | $5.20M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.60M derived: sum of 2 quarters · filed 2026-03-12 | $4.90M derived: sum of 3 quarters · filed 2026-03-12 | $5.00M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.30M derived: sum of 2 quarters · filed 2025-11-12 | $1.40M 10-Q · filed 2025-11-12 | $1.50M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $400.00K 10-Q · filed 2025-08-12 | $500.00K derived: sum of 3 quarters · filed 2025-08-12 | $600.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-07 | $200.00K derived: sum of 2 quarters · filed 2025-05-07 | $300.00K derived: sum of 3 quarters · filed 2025-05-07 | $400.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $200.00K derived: sum of 2 quarters · filed 2025-03-18 | $300.00K derived: sum of 3 quarters · filed 2025-03-18 | $300.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $200.00K derived: sum of 2 quarters · filed 2024-11-12 | $200.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $100.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $100.00K 10-K · filed 2024-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |